Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Abbott Laboratories, consolidated balance sheet: assets (quarterly data)

US$ in millions

	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash and cash equivalents	6,951)	6,532)	7,616)	7,558)	6,987)	6,284)	6,896)	6,709)	7,835)	9,161)	9,882)	9,594)	8,937)	7,675)	9,799)	9,302)	8,658)	8,054)	6,838)	4,480)	4,763)	3,377)
Short-term investments	331)	312)	351)	230)	232)	367)	383)	338)	320)	371)	288)	313)	353)	483)	450)	390)	286)	318)	310)	251)	274)	291)
Trade receivables, less allowances	7,972)	7,327)	6,925)	7,051)	6,854)	6,605)	6,565)	6,499)	6,172)	6,020)	6,218)	6,408)	7,199)	7,179)	6,487)	6,405)	6,113)	6,096)	6,414)	5,649)	5,140)	5,292)
Finished products	4,319)	4,063)	3,700)	4,173)	4,060)	4,063)	3,946)	3,847)	4,004)	3,944)	3,805)	3,407)	3,570)	3,470)	3,081)	3,048)	3,118)	3,219)	3,030)	3,173)	3,240)	2,873)
Work in process	962)	890)	840)	877)	880)	881)	807)	888)	845)	805)	680)	726)	710)	695)	694)	710)	796)	773)	712)	721)	675)	615)
Materials	1,673)	1,686)	1,654)	1,763)	1,874)	1,883)	1,817)	1,915)	2,022)	1,924)	1,688)	1,601)	1,619)	1,526)	1,382)	1,503)	1,525)	1,395)	1,270)	1,258)	1,287)	1,080)
Inventories	6,954)	6,639)	6,194)	6,813)	6,814)	6,827)	6,570)	6,650)	6,871)	6,673)	6,173)	5,734)	5,899)	5,691)	5,157)	5,261)	5,439)	5,387)	5,012)	5,152)	5,202)	4,568)
Prepaid expenses and other receivables	2,260)	2,343)	2,570)	2,150)	2,232)	2,293)	2,256)	2,468)	2,307)	2,152)	2,663)	2,796)	2,568)	2,401)	2,346)	2,134)	2,131)	1,962)	1,867)	1,858)	1,842)	1,970)
Current assets	24,468)	23,153)	23,656)	23,802)	23,119)	22,376)	22,670)	22,664)	23,505)	24,377)	25,224)	24,845)	24,956)	23,429)	24,239)	23,492)	22,627)	21,817)	20,441)	17,390)	17,221)	15,498)
Investments	958)	907)	886)	912)	877)	818)	799)	788)	799)	776)	766)	764)	734)	763)	816)	812)	805)	832)	821)	803)	776)	790)
Property and equipment, at cost	24,472)	23,418)	22,740)	22,857)	22,061)	22,055)	21,933)	21,111)	20,926)	20,605)	20,212)	19,306)	19,458)	19,521)	19,364)	19,182)	19,074)	18,697)	18,793)	17,972)	17,374)	16,707)
Accumulated depreciation and amortization	(13,077)	(12,486)	(12,082)	(12,236)	(11,828)	(11,948)	(11,779)	(11,559)	(11,477)	(11,323)	(11,050)	(10,617)	(10,640)	(10,613)	(10,405)	(10,351)	(10,258)	(9,865)	(9,764)	(9,352)	(9,031)	(8,800)
Net property and equipment	11,395)	10,932)	10,658)	10,621)	10,233)	10,107)	10,154)	9,552)	9,449)	9,282)	9,162)	8,689)	8,818)	8,908)	8,959)	8,831)	8,816)	8,832)	9,029)	8,620)	8,343)	7,907)
Intangible assets, net of amortization	5,920)	6,261)	6,647)	7,352)	7,827)	8,296)	8,815)	9,282)	9,834)	10,006)	10,454)	10,850)	11,592)	12,225)	12,739)	13,312)	13,681)	14,181)	14,784)	15,208)	15,783)	16,265)
Goodwill	23,952)	23,359)	23,108)	23,658)	23,308)	23,383)	23,679)	23,277)	23,258)	22,927)	22,799)	22,284)	22,744)	23,179)	23,231)	23,299)	23,485)	23,384)	23,744)	23,338)	23,082)	22,927)
Deferred income taxes and other assets	17,306)	16,836)	16,459)	8,011)	7,653)	7,487)	7,097)	6,527)	6,509)	6,426)	6,033)	5,369)	5,358)	5,503)	5,212)	4,049)	3,855)	3,739)	3,729)	3,684)	3,571)	3,390)
Long-term assets	59,531)	58,295)	57,758)	50,554)	49,898)	50,091)	50,544)	49,426)	49,849)	49,417)	49,214)	47,956)	49,246)	50,578)	50,957)	50,303)	50,642)	50,968)	52,107)	51,653)	51,555)	51,279)
Total assets	83,999)	81,448)	81,414)	74,356)	73,017)	72,467)	73,214)	72,090)	73,354)	73,794)	74,438)	72,801)	74,202)	74,007)	75,196)	73,795)	73,269)	72,785)	72,548)	69,043)	68,776)	66,777)

The analysis of the presented financial data over multiple quarters reveals several noteworthy trends across various balance sheet components.

Cash and Cash Equivalents: The cash and cash equivalents show initial growth from March 2020 through December 2021, peaking around the end of 2021. There is a subsequent decline in early 2023, followed by some fluctuations without a clear upward or downward trend through mid-2025.
Short-term Investments: Short-term investments remain relatively stable during the entire period, with minor fluctuations around the 300 million US$ mark, showing no significant trend upward or downward.
Trade Receivables: Trade receivables increased steadily from March 2020, peaking in late 2024 and early 2025. This steady growth could indicate increasing sales or extended credit terms over the period.
Inventories (Finished Products, Work in Process, Materials): Finished products demonstrate growth over the period with some fluctuations, peaking in late 2024 and early 2025. Work in process inventories also grew but with more variability, indicating possible changes in production stages. Material inventories consistently increased until early 2023, followed by a slight decline, suggesting changing procurement or usage patterns.
Total Inventories: Overall inventory levels display an upward trend from 2020 through early 2023, then moderate fluctuations with a slight decline followed by recovery towards mid-2025.
Prepaid Expenses and Other Receivables: This category fluctuates without a clear long-term trend, with evident peaks and troughs occurring throughout the period, suggesting varying payment patterns or timing differences in expenses and receivables.
Current Assets: Current assets exhibit growth from early 2020 to early 2021, reaching a peak around March 2021, then fluctuating but generally maintaining higher levels than the start of the period without significant long-term decline or growth thereafter.
Long-term Investments and Property, Plant, and Equipment: Investments remain relatively flat with slight increases towards the end of the period. Property and equipment costs steadily rise over time, indicating ongoing capital expenditure. Accumulated depreciation and amortization also increase steadily, reflecting ongoing usage and aging of assets. Net property and equipment values fluctuate but show a general upward trajectory indicating asset base growth.
Intangible Assets and Goodwill: Intangible assets show a clear declining trend throughout the period, indicating systematic amortization or impairment. Goodwill remains relatively stable, with small fluctuations but no notable long-term increase or decrease.
Deferred Income Taxes and Other Assets: Deferred income taxes and other assets rise steadily, with a sharp increase beginning in early 2025, which might indicate new tax-related regulatory changes or adjustments in asset valuation.
Total Assets: Total assets increase progressively from March 2020 through mid-2025, with a large jump occurring in early 2025. This overall growth is driven mostly by increases in prepaid expenses, trade receivables, property and equipment, and deferred tax assets despite some decreases in intangible assets.

In summary, the financial data presents a picture of steady growth in underlying asset bases, with continued investments in property and equipment, increasing receivables, and inventory build-up, alongside amortization of intangibles. The increases in deferred tax assets and total asset values in recent quarters are particularly notable and warrant further examination. Liquidity appears to fluctuate moderately, with cash levels dipping after 2021 but maintaining a somewhat stable profile through the latest reported periods.

Assets: Selected Items

Download chart

Current Assets: Selected Items

Download chart

Abbott Laboratories (NYSE:ABT)

Balance Sheet: Assets Quarterly Data

Assets: Selected Items

Current Assets: Selected Items

Balance Sheet: Assets
Quarterly Data